HNSCC patients with low NETs signatures tended to express higher levels of immune checkpoints, including CD274 and CTLA4, and responded better to targeted therapies using afatinib, erlotinib, ibrutinib and lapatinib. This evidence concerns the gene CTLA4 and head and neck squamous cell carcinoma.